*Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, Pisa University Hospital, University of Pisa, Pisa, Italy.
†Department of Medical Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
‡Department of Oncology, Medical Oncology Unit, Pisa University Hospital, University of Pisa, Pisa, Italy.
§Surgical Pathology Unit, ASL1 Massa-Carrara, Tuscany, Italy.
Gastrointestinal stromal tumors (GISTs) strongly express a receptor tyrosine kinase (RTK, c-KIT-CD117) harboring a KIT mutation that causes constitutive receptor activation leading to the development and growth of tumors; 35% of GISTs without KIT mutations have platelet-derived growth factor receptor alpha (PDGFRA) mutations, and the type of mutation plays an important role in the response to treatment. This study aimed to establish the frequency of stop codon mutations in the RTKs,
Seventy-nine GISTs were analyzed for both
We found three rare
The association between stop codon mutations in